GSGardar Sveinbjornsson

Gardar Sveinbjornsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gardar Sveinbjornsson has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Resistant Hypertension Variants Link to Hyperaldosteronism and Potassium Levels

    by Vinicius Tragante, Patrick Sulem, Gudmar Thorleifsson, Michael L. Frigge, Joseph G. Arthur, Folkert W. Asselbergs, Karina Banasik, Søren Brunak, Alex H. Christensen, Dana C. Crawford, et al.

    BACKGROUND: We aimed to characterize the genetic architecture of resistant hypertension (rHTN), which affects up to 18% of hypertensive individuals and increases cardiovascular disease risk. METHODS: We conducted a genome-wide association study on rHTN, defined as use of 3 or more concomitant antihypertensive drugs for at least 6 months without reaching blood pressure target (in the 3-drug case), comparing it to controlled hypertension (cHTN), in which persons on 1 or 2 antihypertensives for at least 6 months reach target BP after 30 days of therapy initiation. The study included 23 508 rHTN cases and 24 393 cHTN controls, identified through drug prescription and blood pressure data from Iceland (deCODE), the UK (UK Biobank), and the US (eMERGE). Further analyses included comparisons with all hypertensive individuals (diagnosed with International Classification of Diseases, Tenth Revision code I10) and normotensives (no hypertension diagnosis). RESULTS: We found 24 rHTN variants, 17 of which used published BP variants as prior. Fifteen risk-increasing rHTN alleles are associated with lower serum potassium and increased hyperaldosteronism risk. Individuals with rHTN and cHTN had lower potassium levels before drug therapy than normotensives. All antihypertensive drug classes increased potassium levels in cHTN, while only aldosterone antagonists increased levels in rHTN. Mendelian randomization analysis was consistent with rHTN being a manifestation of hyperaldosteronism. The variant conferring the largest effect on both rHTN and hyperaldosteronism is a stop-gain variant in ENPEP in the aldosterone pathway. CONCLUSIONS: We discovered sequence variants that have different effects on rHTN and cHTN. Our study indicates that genetically determined hyperaldosteronism may be largely accountable for rHTN.


  • Open Access

    Sequence variants affecting fetal globin expression pointing to potential drug targets

    by Magnus Magnusson, Gudjon Oskarsson, Sarnaver Mwende, Katla Kristjansdottir, Asgeir Sigurdsson, Matthias Valdimarsson, Olafur Stefansson, Gisli Halldorsson, Garðar Sveinbjornsson, Vinicius Tragante, et al.

    High fetal hemoglobin level is the most important predictor of favorable clinical outcome in sickle cell disease. We carried out a genome-wide association study (GWAS) on estimated fetal beta globin RNA expression ratio (FGR) using blood RNA sequence data from 22,093 adult Icelanders. In addition to the well-known BCL11A, HBB/HBG2 and HBS1L-MYB loci, we found 33 loci associated with FGR conditioned on variants at these 3 loci (cFGR). We identified fourteen candidate causal genes at the 33 loci. In the ZBTB7A, GFI1B, ZFPM1, and ALAS2 genes we identified rare loss-of-function variants that associate with large effect on cFGR. A rare variant in ZBTB7A, which had the largest increasing effect on cFGR, generates an alternative upstream inframe ATG in an erythroid specific transcript encoding an addition of 119 amino acids to the protein, highlighting a potential therapeutic target. Furthermore, rare variants with large effects in ALAS2 and GFI1B implicate the heme biosynthesis pathway and isoform specific role of GFI1B in fetal hemoglobin regulation.

  • Open Access

    A frameshift variant in PKP2 can be associated with a complex phenotype in sudden cardiac death: a case report

    by Gustav A Davidsson, Gudny A Arnadottir, Gardar Sveinbjornsson, Helga Ottarsdottir, David O Arnar

  • Open Access

    Missense variants in FRS3 affect body mass index in populations of diverse ancestries

    by Andrea B. Jonsdottir, Gardar Sveinbjornsson, Rosa B. Thorolfsdottir, Max Tamlander, Vinicius Tragante, Thorhildur Olafsdottir, Solvi Rognvaldsson, Asgeir Sigurdsson, Hannes P. Eggertsson, Hildur M. Aegisdottir, et al.

    Obesity is associated with adverse effects on health and quality of life. Improved understanding of its underlying pathophysiology is essential for developing counteractive measures. To search for sequence variants with large effects on BMI, we perform a multi-ancestry meta-analysis of 13 genome-wide association studies on BMI, including data derived from 1,534,555 individuals of European ancestry, 339,657 of Asian ancestry, and 130,968 of African ancestry. We identify an intergenic 262,760 base pair deletion at the MC4R locus that associates with 4.11 kg/m2 higher BMI per allele, likely through downregulation of MC4R. Moreover, a rare FRS3 missense variant, p.Glu115Lys, only found in individuals from Finland, associates with 1.09 kg/m2 lower BMI per allele. We also detect three other low-frequency FRS3 missense variants that associate with BMI with smaller effects and are enriched in different ancestries. We characterize FRS3 as a BMI-associated gene, encoding an adaptor protein known to act downstream of BDNF and TrkB, which regulate appetite, food intake, and energy expenditure through unknown signaling pathways. The work presented here contributes to the biological foundation of obesity by providing a convincing downstream component of the BDNF-TrkB pathway, which could potentially be targeted for obesity treatment.


  • Open Access

    Rare loss-of-function variants in HECTD2 and AKAP11 confer risk of bipolar disorder

    by Thorgeir E. Thorgeirsson, Vinicius Tragante, Gardar Sveinbjornsson, Gudrun A. Jonsdottir, G. Bragi Walters, Erna V. Ivarsdottir, Gudny A. Arnadottir, Arni Sturluson, Brynjar O. Jensson, Run Fridriksdottir, et al.

    Bipolar disorder is a highly heritable psychiatric disorder; genome-wide association studies of bipolar disorder have yielded over 60 risk loci harboring common variants. To harness the information contained in rare loss-of-function (LOF) variants, holding promise for informing on the underlying biology, we performed a variant burden analysis for bipolar disorder using gene-based aggregation of LOF variants in whole-genome sequencing data from Iceland (4,197 cases, more than 200,000 controls) and the UK Biobank (1,881 cases, 426,622 controls). We found that HECTD2 was associated with bipolar disorder and confirmed it using the Bipolar Exome dataset. Meta-analysis with Bipolar Exome also revealed that LOF variants in AKAP11 were associated with bipolar disorder. Both associations with bipolar disorder are new, but AKAP11 has previously been associated with psychosis and schizophrenia. The products of AKAP11 and HECTD2 interact with GSK3β, a protein inhibited by lithium, the most effective mood stabilizer available to treat bipolar disorder.


  • Top Cited Papers

    Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases

    by Carolina Roselli, Ida Surakka, Morten S Olesen, Gardar Sveinbjornsson, Nicholas A Marston, Seung Hoan Choi, Hilma Holm, Mark Chaffin, Daniel Gudbjartsson, Matthew C Hill, et al.

    Atrial fibrillation (AF) is the most common heart rhythm abnormality and is a leading cause of heart failure and stroke. This large-scale meta-analysis of genome-wide association studies increased the power to detect single-nucleotide variant associations and found more than 350 AF-associated genetic loci. We identified candidate genes related to muscle contractility, cardiac muscle development and cell–cell communication at 139 loci. Furthermore, we assayed chromatin accessibility using assay for transposase-accessible chromatin with sequencing and histone H3 lysine 4 trimethylation in stem cell-derived atrial cardiomyocytes. We observed a marked increase in chromatin accessibility for our sentinel variants and prioritized genes in atrial cardiomyocytes. Finally, a polygenic risk score (PRS) based on our updated effect estimates improved AF risk prediction compared to the CHARGE-AF clinical risk score and a previously reported PRS for AF. The doubling of known risk loci will facilitate a greater understanding of the pathways underlying AF.


  • Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk

    by Seung Hoan Choi, Sean J Jurgens, Ling Xiao, Matthew C Hill, Christopher M Haggerty, Garðar Sveinbjörnsson, Valerie N Morrill, Nicholas A Marston, Lu-Chen Weng, James P Pirruccello, et al.

    Atrial fibrillation (AF) is a prevalent and morbid abnormality of the heart rhythm with a strong genetic component. Here, we meta-analyzed genome and exome sequencing data from 36 studies that included 52,416 AF cases and 277,762 controls. In burden tests of rare coding variation, we identified novel associations between AF and the genes MYBPC3, LMNA, PKP2, FAM189A2 and KDM5B. We further identified associations between AF and rare structural variants owing to deletions in CTNNA3 and duplications of GATA4. We broadly replicated our findings in independent samples from MyCode, deCODE and UK Biobank. Finally, we found that CRISPR knockout of KDM5B in stem-cell-derived atrial cardiomyocytes led to a shortening of the action potential duration and widespread transcriptomic dysregulation of genes relevant to atrial homeostasis and conduction. Our results highlight the contribution of rare coding and structural variants to AF, including genetic links between AF and cardiomyopathies, and expand our understanding of the rare variant architecture for this common arrhythmia.


  • Top Cited Papers
    Open Access

    Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes

    by Albert Henry, Xiaodong Mo, Chris Finan, Mark D. Chaffin, Doug Speed, Hanane Issa, Spiros Denaxas, James S. Ware, Sean L. Zheng, Anders Malarstig, et al.

    Heart failure (HF) is a major contributor to global morbidity and mortality. While distinct clinical subtypes, defined by etiology and left ventricular ejection fraction, are well recognized, their genetic determinants remain inadequately understood. In this study, we report a genome-wide association study of HF and its subtypes in a sample of 1.9 million individuals. A total of 153,174 individuals had HF, of whom 44,012 had a nonischemic etiology (ni-HF). A subset of patients with ni-HF were stratified based on left ventricular systolic function, where data were available, identifying 5,406 individuals with reduced ejection fraction and 3,841 with preserved ejection fraction. We identify 66 genetic loci associated with HF and its subtypes, 37 of which have not previously been reported. Using functionally informed gene prioritization methods, we predict effector genes for each identified locus, and map these to etiologic disease clusters through phenome-wide association analysis, network analysis and colocalization. Through heritability enrichment analysis, we highlight the role of extracardiac tissues in disease etiology. We then examine the differential associations of upstream risk factors with HF subtypes using Mendelian randomization. These findings extend our understanding of the mechanisms underlying HF etiology and may inform future approaches to prevention and treatment.


  • Top Cited Papers
    Open Access

    Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyopathy

    by Sean L. Zheng, Albert Henry, Douglas Cannie, Michael Lee, David Miller, Kathryn A. McGurk, Isabelle Bond, Xiao Xu, Hanane Issa, Catherine Francis, et al.

    Dilated cardiomyopathy (DCM) is a leading cause of heart failure and cardiac transplantation. We report a genome-wide association study and multi-trait analysis of DCM (14,256 cases) and three left ventricular traits (36,203 UK Biobank participants). We identified 80 genomic risk loci and prioritized 62 putative effector genes, including several with rare variant DCM associations (MAP3K7, NEDD4L and SSPN). Using single-nucleus transcriptomics, we identify cellular states, biological pathways, and intracellular communications that drive pathogenesis. We demonstrate that polygenic scores predict DCM in the general population and modify penetrance in carriers of rare DCM variants. Our findings may inform the design of genetic testing strategies that incorporate polygenic background. They also provide insights into the molecular etiology of DCM that may facilitate the development of targeted therapeutics.


  • Open Access

    Sequence variants associated with BMI affect disease risk through BMI itself

    by Gudmundur Einarsson, Gudmar Thorleifsson, Valgerdur Steinthorsdottir, Florian Zink, Hannes Helgason, Thorhildur Olafsdottir, Solvi Rognvaldsson, Vinicius Tragante, Magnus O. Ulfarsson, Gardar Sveinbjornsson, et al.

    Mendelian Randomization studies indicate that BMI contributes to various diseases, but it’s unclear if this is entirely mediated by BMI itself. This study examines whether disease risk from BMI-associated sequence variants is mediated through BMI or other mechanisms, using data from Iceland and the UK Biobank. The associations of BMI genetic risk score with diseases like fatty liver disease, knee replacement, and glucose intolerance were fully attenuated when conditioned on BMI, and largely for type 2 diabetes, heart failure, myocardial infarction, atrial fibrillation, and hip replacement. Similar attenuation was observed for chronic kidney disease and stroke, though results varied. Findings were consistent across sexes, except for myocardial infarction. Residual effects may result from temporal BMI changes, pleiotropy, measurement error, non-linear relationships, non-collapsibility, or confounding. The attenuation extent of BMI genetic risk score on disease associations suggests the potential impact of reducing BMI on disease risk.